How tumor DNA ends up in the blood
Dying cells shed fragments of their DNA into the bloodstream as cell-free DNA. In a person with cancer, a fraction of that cfDNA comes from tumor cells and carries the tumor's specific mutations. A liquid biopsy sequences plasma cfDNA and looks for those tumor-derived variants, allowing information about the cancer to be gathered from a blood draw rather than a tissue biopsy.
The tumor-derived fraction is often very small, especially in early or low-burden disease, so the assays must distinguish rare mutant molecules from a large background of normal cfDNA. This sensitivity challenge is why detection in minimal-residual-disease and early-detection settings is harder than in advanced disease with high tumor burden.
What clinicians use it for
Liquid biopsy can identify actionable mutations to guide targeted therapy, track whether a tumor is responding by watching the mutant fraction rise or fall, and detect emerging resistance mutations before they show on imaging. It is also studied for minimal residual disease after treatment. A negative result does not rule out cancer, since some tumors shed little DNA, so it complements rather than replaces tissue diagnosis.
What the ctDNA trace is showing you
This is general educational information, not medical advice. The clinical roles of ctDNA are evolving and vary by cancer type and assay; interpretation belongs with the treating team.